Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for IMNN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 10.16M
March 31, 2026 -0.0018M
December 31, 2025 7.191M
September 30, 2025 4.963M
June 30, 2025 4.826M
March 31, 2025 0.1057M
December 31, 2024 -0.0033M
September 30, 2024 9.064M
June 30, 2024 0.00
March 31, 2024 0.00
December 31, 2023 0.0302M
September 30, 2023 0.0783M
June 30, 2023 -6.221M
March 31, 2023 2.474M
December 31, 2022 0.4473M
September 30, 2022 -0.064M
June 30, 2022 6.339M
March 31, 2022 0.00
December 31, 2021 0.00
September 30, 2021 -0.0083M
June 30, 2021 14.32M
March 31, 2021 40.46M
December 31, 2020 2.561M
September 30, 2020 -3.132M
June 30, 2020 12.76M
Date Value
March 31, 2020 5.795M
December 31, 2019 1.669M
September 30, 2019 1.712M
June 30, 2019 2.709M
March 31, 2019 1.755M
December 31, 2018 -0.3781M
September 30, 2018 0.00
June 30, 2018 9.725M
March 31, 2018 1.237M
December 31, 2017 25.72M
September 30, 2017 4.163M
June 30, 2017 3.256M
March 31, 2017 3.316M
December 31, 2016 0.2781M
September 30, 2016 -1.040M
June 30, 2016 4.428M
March 31, 2016 -0.9885M
December 31, 2015 -0.3799M
September 30, 2015 -1.011M
June 30, 2015 6.352M
March 31, 2015 -0.8784M
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 4.964M
March 31, 2014 13.81M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Phio Pharmaceuticals Corp. 0.00
Agenus, Inc. 14.68M
Amgen, Inc. -1.482B
Anika Therapeutics, Inc. -0.701M
BioCryst Pharmaceuticals, Inc. -10.79M